Please login to the form below

Not currently logged in

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

AstraZeneca AZ headquarters London UK 

With a renewed takeover attempt by Pfizer looking increasingly unlikely, AstraZeneca (AZ) is trumpeting its independent future in documents released today ahead of an investors meeting.

Central to its optimism is a growing pipeline in cancer, and specifically immuno-oncology, which is now emerging as a "sixth growth platform" to sit alongside respiratory medicine, diabetes, the revitalised antithrombotic Brilinta (ticagrelor), Japan and emerging markets.

Oncology is expected to account for around a quarter of AZ's predicted $45bn in annual revenues by 2023, driven by the immuno-oncology portfolio that includes 13 combination trials already underway and 16 at the planning stages.

The company has also brought forward its anticipated filing date for non-small cell lung cancer (NSCLC) candidate AZD9291, an orally-active epidermal growth factor receptor (EGFR) inhibitor, to the second quarter of 2015.

AZ said in May - at the height of its defense against Pfizer's £69bn ($120bn) takeover bid - that AZD9291 could be a $3bn-a-year product at peak.

After a couple of years of investing heavily in licensing and partnering to bolster what had previously been considered a somewhat sparse pipeline, the company now has 14 drugs in phase III trials or at the registration stage, which could generate 8-10 new approvals in 2015-2016.

In addition to its six growth platforms, the company is also building a presence in neuroscience and infection through partnerships and licensing, according to AZ.

"We have more than doubled the number of potential medicines in our late-stage pipeline since 2012 and we are on track to return to growth by 2017," said chief executive Pascal Soriot in the trading update, which indicated the transformation in R&D has taken place faster than expected.

"We are building a sustainable, more durable and profitable company," he added. "The tangible results being delivered reinforce our confidence that we will achieve our target of delivering revenues of over $45bn by 2023."

The update comes just over week before the moratorium on a second Pfizer bid for AZ comes to a close, although changes to US taxation regulations in recent weeks designed to minimise the benefits of tax inversion deals have led to suggestions Pfizer will look elsewhere for a merger or engage in smaller-scale deals such as its $2.8bn immuno-oncology alliance with Merck KGaA.  

Article by
Phil Taylor

18th November 2014

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...